Health Care & Life Sciences » Biotechnology | Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.36
Market Cap
$2.52 B
Shares Outstanding
145.51 M
Public Float
129.63 M

Profile

Address
11388 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.halozyme.com
Updated 07/08/2019
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

Financials

View All

Helen I. Torley
President, Chief Executive Officer & Director
Bernadette M. Connaughton
Director